home > pmps > autumn 2019 > the impact of emerging trends
Pharmaceutical Manufacturing and Packing Sourcer

The Impact of Emerging Trends

Quality assurance is critical in all industries, but in the pharmaceutical supply chain, the cost at stake is higher than most. As the industry shifts towards high-precision, low-volume therapies, pharma shipments become more sensitive, more expensive, and there are significant repercussions for temperature excursions or delayed deliveries. With the global pharma cold chain expected to reach $18 billion in spending by 2022, the impact of errors during transportation can result in compounded inefficiencies and increased costs throughout the entire supply chain, which ultimately affects the patients relying on these treatments.

Today, more rigorous transportation and storage requirements, such as advanced temperature control, sophisticated packaging, and additional monitoring and tracking requirements, are shaping the pharma distribution industry. The supply chain’s complexity is expanding; there is growing local and multi-jurisdictional regulatory oversight and increasing data requirements – all while precise delivery windows are shrinking. These shifting industry dynamics have led to significant changes in the way many pharma products are handled and highlight the industry’s need for high-quality specialty logistics solutions. Specifically, these solutions and their providers must address three critical drivers of change to maintain quality control: increasingly innovative therapies, expanding regulations, and the continued globalisation of the supply chain.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Dr Ruediger Lomb is Vice President of Global Quality and Compliance for World Courier, as well as for Integrated Commercialisation Solutions, which are both AmerisourceBergen companies. In his role, Ruediger oversees the quality programme for both entities, ensuring facility and process compliance with all current and future GxP standards such as relevant FDA guidelines, the most recent EU GMP guidelines, and other relevant quality standards. He is a licensed pharmacist and holds a PhD in Pharmaceutical Biochemistry.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement